moxalactam has been researched along with Prostatic Hyperplasia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, T; Fujioka, T; Hata, M; Hayakawa, M; Matsuzaki, S; Nagakura, K; Nakamura, H; Takao, M | 1 |
| Hasegawa, S; Hattori, R; Kinukawa, T; Matsuura, O; Ohshima, S; Ono, Y; Takeuchi, N | 1 |
| Fujisawa, M; Inada, F; Mizunaga, M; Morikawa, M; Nakata, Y; Osanai, H; Yachiku, S | 1 |
3 other study(ies) available for moxalactam and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Concentration level of latamoxef sodium (LMOX) in prostatic tissue].
Topics: Aged; Anti-Bacterial Agents; Humans; Injections, Intravenous; Male; Middle Aged; Moxalactam; Premedication; Prostate; Prostatectomy; Prostatic Hyperplasia; Prostatitis | 1985 |
[A study of prostatic tissue levels of latamoxef, cefoperazone and cefotaxime].
Topics: Aged; Aged, 80 and over; Biological Transport; Cefoperazone; Cefotaxime; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Moxalactam; Premedication; Prostate; Prostatectomy; Prostatic Hyperplasia | 1986 |
[Study of levels of latamoxef in prostatic tissue and bladder mucosal tissue].
Topics: Dose-Response Relationship, Drug; Drug Resistance, Microbial; Escherichia coli; Humans; Male; Moxalactam; Mucous Membrane; Prostate; Prostatic Hyperplasia; Urinary Bladder; Urinary Bladder Neoplasms | 1987 |